Healthcare Professionals

The 4th edition of the original full-length Guidelines, published in June 2022, includes a full review of the evidence supporting almost each recommendation for physicians to know all the facts…

Physicians in Norway have initiated recruitment of chronically transfused patients with haematological malignancies, including myelodysplastic syndrome (MDS), to receive transfusions using RBCs processed and stored with the Hemanext ONE® system.…

The newly issued publication ‘Basic Recommendations in Brief for Treating Physicians’, based on and complementing the ‘Guidelines for the Management of Transfusion Dependent Thalassaemia (4th Edition – 2021)’, is an…

Every single one of us has the ability to make a difference, large or small, and together we can make real progress in raising valuable awareness about thalassaemia and its…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) tablets for the treatment of hemolytic…

“Although thalassemia has always been endemic in Europe, especially in southern European countries such as Cyprus, Greece and Italy, the disease now knows no borders and constitutes an increasing health,…

Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…

A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…